Switzerland – COVID-19 vaccine from Johnson & Johnson: Swissmedic approves the third vaccine against COVID-19

Application for authorisation submitted by Janssen-Cilag AG approved

Par
RIS.WORLD
-
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) - updated information
COVID-19 vaccine from Johnson & Johnson: Swissmedic approves the third vaccine against COVID-19

Swissmedic has temporarily authorised the « Covid-19 vaccine Janssen » developed by the pharmaceutical corporation Johnson & Johnson for people aged 18 and over. This brings to three the number of vaccines officially authorised for distribution in Switzerland for the prevention of COVID-19. The vector vaccine based on a human adenovirus only needs to be administered as a single dose. The submitted study data show an average efficacy of 66.9 percent in the investigated age groups.

On 7 December 2020, Janssen-Cilag AG – a company in the Johnson & Johnson healthcare group – submitted an application to Swissmedic for the authorisation of its vaccine candidate (Ad26.COV2.S). Following a careful review of all the submitted documentation, Swissmedic has granted the « COVID-19 Vaccine Janssen » temporary authorisation. The HMEC (Human Medicines Expert Committee), Swissmedic’s external advisory body, voiced its support for this decision during an extraordinary meeting…

ARTICLES CONNEXESPLUS DE L'AUTEUR